Tranquilli Financial Advisor LLC Has $706,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Tranquilli Financial Advisor LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 72.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,114 shares of the medical instruments supplier’s stock after purchasing an additional 1,306 shares during the period. Tranquilli Financial Advisor LLC’s holdings in Becton, Dickinson and Company were worth $706,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in shares of Becton, Dickinson and Company by 0.8% in the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after acquiring an additional 106,616 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Becton, Dickinson and Company by 1.8% during the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock valued at $1,510,050,000 after purchasing an additional 111,101 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after buying an additional 460,440 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in Becton, Dickinson and Company by 31.0% during the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after acquiring an additional 673,568 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BDX shares. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $283.00.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 597 shares of Becton, Dickinson and Company stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the transaction, the executive vice president now owns 5,544 shares of the company’s stock, valued at $1,311,211.44. The trade was a 9.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,844 shares of company stock valued at $2,210,716. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0 %

NYSE BDX opened at $247.57 on Tuesday. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $71.80 billion, a PE ratio of 41.68, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The firm has a 50 day moving average of $230.53 and a two-hundred day moving average of $233.83.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.42 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.68%. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Becton, Dickinson and Company declared that its board has initiated a stock buyback plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.